cjc+ipa blend
CJC-1295 plus ipamorelin pairs GHRH- and ghrelin-receptor signaling to stimulate growth-hormone release. No human outcome trial has shown that a marketed blend improves sleep, recovery, or body composition, and marketed products may contain different CJC constructs.
GHRH analog + ghrelin-receptor agonist
- GHRH analog + ghrelin-receptor agonist
- CJC identity and component amounts must be specified
What does CJC + ipamorelin actually contain?
The blend contains two peptides, but ‘CJC’ may mean CJC-1295 with DAC or material sold as CJC no DAC. Only the identified DAC form has multi-day human exposure data.
Why does DAC matter?
The drug-affinity-complex modification changes how the CJC component persists. The human long-acting data belong to the identified DAC material. A short name, a total vial weight or a claim of purity does not resolve which construct is present.
FDA · CJC forms and human exposure
Regulatory safety assessment
FDA · CJC forms and human exposure
The assessment distinguishes CJC-1295 forms, including the drug-affinity-complex construct. Human results for that long-acting material cannot establish the exposure, efficacy or safety of a product labeled only CJC or no DAC.
Read the original sourceHas this exact combination been tested?
The cited records contain no controlled clinical outcome study of the specified CJC-1295/ipamorelin finished blend. Component studies and discussions of combined use do not establish a finished-blend outcome.
Exact combination · no controlled outcome study
Literature and registry record set
PubMed and public trial records.
The cited records contain no controlled outcome study of a chemically specified CJC-1295/ipamorelin fixed blend.
- The cited records contain no published or registered controlled study of a CJC-1295/ipamorelin fixed blend.
Does a bigger GH pulse mean better results?
The pairing can raise growth hormone through GHRH- and ghrelin-receptor pathways. Studies have not linked the size of that pulse to fat loss, sleep, or injury healing.
| Question | What the evidence can support |
|---|---|
| Sleep | Validated sleep outcomes with a comparison group, not reports of feeling more rested. |
| Body composition | Measured fat and lean-tissue changes, with diet, training and other hormones accounted for. |
| Recovery | Function, symptoms and injury-specific outcomes, rather than a hormone measurement alone. |
FDA · CJC forms and human exposure
Regulatory safety assessment
FDA · CJC forms and human exposure
The assessment distinguishes CJC-1295 forms, including the drug-affinity-complex construct. Human results for that long-acting material cannot establish the exposure, efficacy or safety of a product labeled only CJC or no DAC.
Read the original sourceEight-man crossover · acute GH release
Acute randomized crossover study
Tiulpakov AN et al. Clinical Endocrinology, 1995. PMID 7586605.
Eight healthy men received intravenous GHRH(1-29) amide, GHRP-2 and their combination in randomized order. The combination increased GH exposure, but did not significantly exceed the sum of the separate responses. No long-term body-composition or functional outcome was tested.
Read the original sourceWhat side effects and unknowns matter?
No study provides an adverse-event rate for the finished blend. FDA describes serious reactions with CJC-1295 and incomplete route-specific safety information for ipamorelin.
Did ipamorelin cause deaths?
FDA notes deaths and other serious events in an intravenous gastric-motility study. That is an observed safety concern, not proof that ipamorelin caused every event. It also cannot be converted into a risk percentage for repeated subcutaneous use.
FDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA identifies incomplete human safety data and peptide impurity or immune-reaction concerns for several ingredients used in these blends. Its CJC-1295 entry reports increased heart rate and a systemic vasodilatory reaction. For ipamorelin, serious events, including deaths, occurred in an intravenous study; this does not establish causation or the risk of other routes. BPC-157, injectable GHK-Cu and KPV have substantial route-specific safety gaps.
Read the original sourceHow long does it last, and is there a studied cycle?
The cited evidence contained no combined exposure curve or outcome-based cycle for the specified blend. Each ingredient can have a different time course. Neither an average of two half-lives nor the long-acting CJC result supplies a validated schedule for a mixed vial.
FDA · CJC forms and human exposure
Regulatory safety assessment
FDA · CJC forms and human exposure
The assessment distinguishes CJC-1295 forms, including the drug-affinity-complex construct. Human results for that long-acting material cannot establish the exposure, efficacy or safety of a product labeled only CJC or no DAC.
Read the original sourceExact combination · no controlled outcome study
Literature and registry record set
PubMed and public trial records.
The cited records contain no controlled outcome study of a chemically specified CJC-1295/ipamorelin fixed blend.
- The cited records contain no published or registered controlled study of a CJC-1295/ipamorelin fixed blend.
Does compounding make it an approved treatment?
A compounded combination does not acquire FDA approval from its ingredients, its prescriber or its pharmacy. A supplier also needs to establish the exact CJC form, amount of each ingredient and the finished preparation’s quality. None of those checks is a substitute for a clinical trial.
FDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA identifies incomplete human safety data and peptide impurity or immune-reaction concerns for several ingredients used in these blends. Its CJC-1295 entry reports increased heart rate and a systemic vasodilatory reaction. For ipamorelin, serious events, including deaths, occurred in an intravenous study; this does not establish causation or the risk of other routes. BPC-157, injectable GHK-Cu and KPV have substantial route-specific safety gaps.
Read the original sourceFDA · CJC forms and human exposure
Regulatory safety assessment
FDA · CJC forms and human exposure
The assessment distinguishes CJC-1295 forms, including the drug-affinity-complex construct. Human results for that long-acting material cannot establish the exposure, efficacy or safety of a product labeled only CJC or no DAC.
Read the original sourceStudies and sources
FDA · CJC forms and human exposure
Regulatory safety assessment
FDA · CJC forms and human exposure
The assessment distinguishes CJC-1295 forms, including the drug-affinity-complex construct. Human results for that long-acting material cannot establish the exposure, efficacy or safety of a product labeled only CJC or no DAC.
Read the original sourceEight-man crossover · acute GH release
Acute randomized crossover study
Tiulpakov AN et al. Clinical Endocrinology, 1995. PMID 7586605.
Eight healthy men received intravenous GHRH(1-29) amide, GHRP-2 and their combination in randomized order. The combination increased GH exposure, but did not significantly exceed the sum of the separate responses. No long-term body-composition or functional outcome was tested.
Read the original sourceFDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA identifies incomplete human safety data and peptide impurity or immune-reaction concerns for several ingredients used in these blends. Its CJC-1295 entry reports increased heart rate and a systemic vasodilatory reaction. For ipamorelin, serious events, including deaths, occurred in an intravenous study; this does not establish causation or the risk of other routes. BPC-157, injectable GHK-Cu and KPV have substantial route-specific safety gaps.
Read the original sourceExact combination · no controlled outcome study
Literature and registry record set
PubMed and public trial records.
The cited records contain no controlled outcome study of a chemically specified CJC-1295/ipamorelin fixed blend.
- The cited records contain no published or registered controlled study of a CJC-1295/ipamorelin fixed blend.
Why is cjc+ipa blend in A tier?
No controlled outcome trial has tested the finished blend. Only the identified DAC form has long-acting human exposure data.